The company is committed to a new category development in areas like adult Immunization with products like Shingrix to make a positive impact to the lives of the patients in India
Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry
Collaboration provides AstraZeneca with exclusive rights to Omniose’s proprietary bioconjugation platform to explore potential vaccines for a broad range of bacterial pathogens
The companies plan to start a pivotal Phase 3 trial in the coming months
The vaccine further advances Pfizer’s vaccine portfolio and builds on more than 20 years of expertise and knowledge in the prevention of meningococcal disease
Over 34 lakh children and 6 lakh pregnant women were administered vaccine doses during the first 2 rounds of IMI 5.0 campaign across the country
Merck continues progress in helping to protect people at risk of Zaire ebolavirus disease
Authorisation will help protect adults 60 years of age and older in 30 European countries* from RSV disease for the first time
_256_384.jpg)
HMD had supplied 921.7 million syringes to the Government of India to facilitate over 2.2 billion Vaccination in India till date
Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time
Subscribe To Our Newsletter & Stay Updated
